6 reports

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Chronic Disease
  • Vaccine

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Drug
  • Allergy Immunotherapy
  • Chronic Disease
  • Vaccine

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Pharmaceutical
  • Therapy
  • Vaccine

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Gene Therapy
  • Ophthalmology
  • Therapy
  • Vaccine

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Gene Therapy
  • Ophthalmology
  • Pharmaceutical
  • Therapy
  • Vaccine